Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
Achilles Therapeutics has been featured as a value stock. Achilles Therapeutics's Q1 EPS sits at $-0.45, which has not changed since last quarter (Q4). Sensus Healthcare saw a decrease in earnings per share from 0.32 in Q4 to $0.2 now. This quarter, Global Cord Blood experienced a decrease in earnings per share, which was $0.17 in Q3 and is now $0.14. BioNTech has reported Q1 earnings per share at $15.97, which has increased by 14.64% compared to Q4, which was 13.93. Most recently, Fonar reported earnings per share at $0.32, whereas in Q2 earnings per share sat at $0.57.
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.